Schering and Merck Are Settling Vytorin Suits
Thursday, August 6, 2009 - 00:14
in Health & Medicine
Merck and Schering-Plough said that they would pay $41.5 million to settle suits claiming they delayed study results on their cholesterol drug Vytorin because the data was unfavorable.